Implementation and evaluation of vancomycin nomogram guidelines in a computerized prescriber-order-entry system

American Journal of Health-System Pharmacy

Volumn 67, Issue 1, 2010, Pages 70-75

  McCluggage, Lauren ^a   Lee, Kimberly ^b   Potter, Teresa ^b   Dugger, Richard ^b   Pakyz, Amy ^c  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b VCU Health System   (United States)

^c U of WI School of Pharmacy   (United States)

Author keywords

Antibiotics; Blood levels; Computers; Dosage; Medication orders; Methodology; Models; Nomograms; Protocols; Vancomycin

Indexed keywords

VANCOMYCIN;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; COMPUTER AIDED DESIGN; COMPUTER SYSTEM; COMPUTERIZED PROVIDER ORDER ENTRY; DRUG BLOOD LEVEL; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; RECOMMENDED DRUG DOSE;

EID: 74049083688     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080625     Document Type: Article

References (10)

1. Wilhelm MP, Estes LE. Vancomycin. Mayo Clin Proc. 1999; 74:928-35.
2. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006; 42(suppl 1):S35-9.
3. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004; 39:1267-84.
4. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009; 66:82-98. [Erratum, Am J Health-Syst Pharm. 2009; 66:887.]
5. Rodman DP, McKnight JT, Rogers T et al. The appropriateness of initial vancomycin dosing. J Fam Pract. 1994; 38:473-7.
6. Karam CM, McKinnon PS, Neuhauser NM et al. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy. 1999; 19:257-66.
7. Charles PG, Ward PB, Johnson PD et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004; 38:448-51.
8. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother. 2003; 47:3040-5.
9. Matzke GR, McGory RW, Halstenson CE et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984; 25:433-7.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002; 39(suppl 1):S1-266.